Cynoplus (Levotiroxina Sódica / Liotironina)
Comparable a: Cynoplus
Sustancia activa: Levotiroxina sódica / Liotironina
Concentración: 30 mcg / 120 mcg por tableta
Presentación: Caja con 50 tabletas
Laboratorio: Grossman
Origen: México
Este medicamento se utiliza para el tratamiento del hipotiroidismo, aportando levotiroxina (T4) y liotironina (T3) para restablecer y mantener niveles adecuados de hormonas tiroideas en el organismo, favoreciendo el metabolismo y diversas funciones fisiológicas.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
THERAPEUTIC INDICATIONS: CYNOPLUS * is indicated for the treatment of hypothyroidism when there is decreased or absent thyroid function, caused by antithyroid agents, radiation therapy, primary atrophy, partial or total removal of the gland or functional alterations of the same. CYNOPLUS * is effective in the treatment of hypothyroidism of any etiology. CYNOPLUS use * as replacement therapy in simple goiter (nontoxic) as a result produces a rapid reduction in the size of the thyroid gland.
CYNOPLUS * has proved useful in the maintenance treatment of hypothyroidism.
CONTRAINDICATIONS: Thyrotoxicosis, unstable angina, acute myocardial infarction. CYNOPLUS * is contraindicated in patients with adrenal insufficiency irreversible, increasing demand for adrenocortical hormones and may cause an acute adrenal crisis.
CAUTIONS: CYNOPLUS * should be administered with caution in patients with cardiovascular diseases, including hypertension. Any cardiovascular complication required a reduction in dosage. Caution should be exercised in patients with coronary artery disease, since the possibility of cardiac arrhythmias may be greater in patients treated with thyroid hormones.
In patients whose hypothyroidism is secondary to hypopituitarism, are likely to coexist adrenal insufficiency.When this happens, the latter should be corrected by corticosteroid prior to administration of thyroid hormones.
RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION: Thyroid hormones do not cross the placental barrier rapidly. Clinical experience indicates that CYNOPLUS * no adverse effects on the fetus when administered during pregnancy. Based on this knowledge, the thyroid replacement therapy to hypothyroid women should not be discontinued during pregnancy.
Thyroid hormones are secreted in minute quantities in breast milk and their use has been associated with serious adverse reactions, however, caution should be exercised when thyroid hormones are administered to women during lactation.
DOSAGE AND ADMINISTRATION: Oral.
CYNOPLUS * is generally administered in one dose, preferably before breakfast.
We recommend starting with half a tablet daily for CYNOPLUS * 1 to 2 weeks. It may subsequently be increased to one tablet daily for 1 to 2 weeks. According to the clinical andlaboratory data, the dose may be increased or decreased, recalling that the final doseneeded varies from patient to patient individually.
In children the dose should be increased every 2 weeks. In elderly patients, CYNOPLUS *should be administered with caution since it is common to the hidden presence of cardiovascular disease. In these cases treatment should be started at low doses and if symptoms or aggravate existing dose should be decreased.
